ESMO 2017 Bladder Cancer

Viewing 1-20 of 21 articles

ESMO 2017: Second-line treatment patterns and outcomes of metastatic bladder cancer patients in clinical practice

ESMO 2017: Outcomes of patients with metastatic urothelial carcinoma with exclusive bone metastases: Focus on a special patient population

ESMO 2017: Identification of genomic features underlying response of muscle-invasive bladder cancer to neoadjuvant sorafenib, gemcitabine, and cisplatin in an open-label, single-arm, phase 2 study

ESMO 2017: Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: A joint study of the EAU-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration

ESMO 2017: Avelumab treatment of metastatic urothelial carcinoma in the phase 1b JAVELIN Solid Tumor study: Updated analysis with ≥6 months of follow-up in all patients

ESMO 2017: Immunotherapy for Urothelial Cancer – Longer Follow-up and Subgroup Analyses: Invited Discussant

ESMO 2017: Urothelial Carcinoma Poster Discussion – Invited Discussant

ESMO 2017: Medical Costs and Health Care Resource Use in Elderly US Patients With Newly Diagnosed Metastatic or Surgically Unresectable Urothelial Carcinoma Using Surveillance, Epidemiology, and End Results (SEER) Medicare Data

ESMO 2017: Real World Treatment Costs and Resource Utilization among Patients with Metastatic Bladder Cancer

ESMO 2017: Comparison of tumor mutational burden in relevant molecular subsets of metastatic urothelial cancer

ESMO 2017: Will RANGE study impact the standard of care in metastatic urothelial carcinoma?

ESMO 2017: A Phase III, Randomized, Double-Blind, Multicenter Study of Adjuvant Nivolumab vs Placebo in Patients with High-Risk Invasive Urothelial Carcinoma (CheckMate 274)

ESMO 2017: Pembrolizumab ± chemotherapy versus chemotherapy in advanced urothelial cancer: Phase 3 KEYNOTE-361 trial

ESMO 2017: RANGE: A randomized, double-blind, placebo controlled phase 3 study of docetaxel with or without ramucirumab in platinum refractory advanced or metastatic urothelial carcinoma

ESMO 2017: Atezolizumab in Platinum-Treated Locally Advanced or Metastatic Urothelial Carcinoma: Post-Progression Outcomes from the Phase 2 IMvigor210 Study

ESMO 2017: Epithelial-mesenchymal transition, T cell infiltration, and outcomes with nivolumab in urothelial cancer

ESMO 2017: Pembrolizumab versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer: mature results from the phase 3 KEYNOTE-045 trial

ESMO 2017: KEYNOTE-045: Pembrolizumab vs Individual Investigator’s Choice of Chemotherapy in Recurrent, Advanced Urothelial Cancer

ESMO 2017: Impact of Tumor Mutation Burden on Nivolumab Efficacy in Second-Line Urothelial Carcinoma Patients: Exploratory Analysis of the Phase II CheckMate 275 Study

ESMO 2017: Ramucirumab plus docetaxel improves progression-free survival in urothelial cancer

1
2